Trikafta 50-25-37.5 MG/75 MG UU 84S
Ended Awarded Last action
- Contract number
- SPE2DR26FFAZ5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $116,095
Award facts
- Contract value 100% obligated
- $116,095.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $116,095.28 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Trikafta 50-25-37.5 mg/75 mg tablets (84-count units). The delivery order, issued on January 30, 2026, with an ultimate completion date of February 2, 2026, was awarded without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This award represents a single delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to support Department of Defense pharmaceutical supply needs.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical pharmaceutical supplier within the federal military medical system since its November 13, 2025 award of the PPV-G GEN V IDC, valued at up to $499,999,999 through December 31, 2036. The company's established track record delivering diverse pharmaceutical products—including specialty biologics, oncology treatments, immunosuppressants, and routine medications—positions it to fulfill the recurring and specialized pharmaceutical requirements of DoD healthcare facilities worldwide. As the sole contractor on this delivery order with no identified subcontractor relationships, DMS Pharmaceutical Group directly supplies the medications necessary to support military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FFAZ5?
SPE2DR26FFAZ5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FFAZ5 worth?
The government has obligated $116,095 on SPE2DR26FFAZ5.
Is contract SPE2DR26FFAZ5 an order under another contract?
Yes. SPE2DR26FFAZ5 is a delivery order under SPE2DR25D9225, an indefinite delivery contract.
Was contract SPE2DR26FFAZ5 competed?
The extent of competition for SPE2DR26FFAZ5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award